Core Points - Neurothera Labs Inc. held its annual and special meeting of shareholders on January 8, 2026, where key decisions were made regarding the company's governance and future plans [1] Group 1: Shareholder Decisions - All nominee directors listed in the management information circular dated December 4, 2025, were elected as directors [2] - Shareholders voted to appoint Dale Matheson Carr-Hilton Labonte LLP as auditors for the upcoming year and authorized the directors to fix their remuneration [2] - A consolidation of common shares was authorized, allowing for a potential consolidation of one post-consolidation share for up to one hundred pre-consolidation shares, subject to the directors' discretion and market conditions [3] - The adoption of a 20% fixed equity incentive plan was approved, pending final approval from the TSX Venture Exchange [4] Group 2: Company Overview - Neurothera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [5]

Q3 Fiscal 2026 Results - Net sales revenue decreased by 34% from $5307 million in Q3 FY25 to $5128 million in Q3 FY26[16] - Organic net sales decreased by 108% with 33% or $173 million of the decline due to tariff-related revenue disruptions[17] - Gross margin decreased by 200 basis points from 489% in Q3 FY25 to 469% in Q3 FY26 primarily due to higher tariffs and less favorable inventory obsolescence[16, 17] - Adjusted EBITDA margin decreased by 350 basis points from 182% in Q3 FY25 to 147% in Q3 FY26 primarily due to lower gross profit margin and a higher SG&A rate[16, 17] - Adjusted diluted EPS decreased from $267 in Q3 FY25 to $171 in Q3 FY26 primarily due to lower adjusted operating income and higher interest expense[16, 17] - Free cash flow decreased from $561 million YTD FY25 to $288 million YTD FY26[16] Tariff Mitigation and Outlook - The company expects to reduce the remaining unmitigated tariff impact to less than $30 million in Fiscal 2026[30] - The company is implementing a dual sourcing strategy to lessen exposure to China manufacturing with a goal of 40% dual sourcing by the end of FY26 and 60% by the end of FY27[30, 33] - The company anticipates consolidated net sales of $1758 to $1773 billion for the full year Fiscal 2026[36] - The company projects adjusted diluted EPS of $325 to $375 for the full year Fiscal 2026[36]

Conference call to be held on Tuesday, February 10, 2026, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 8, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year of 2025 before the Nasdaq market opens on Tuesday, February 10, 2026. InMode is currently finalizing its financial results for the fourth quarter and full year of 2025. While complete finan ...

INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Calumet, Inc. (NASDAQ: CLMT) (the "Company" or "Calumet") today announced that its wholly owned subsidiaries, Calumet Specialty Products Partners, L.P. (the "Partnership") and Calumet Finance Corp. (together with the Partnership, the "Issuers"), priced their private placement (the "Offering") under Rule 144A and Regulation S under the Securities Act of 1933, as amended (the "Securities Act"), of $405 million in aggregate principal amount of 9.75% Senior Notes due ...

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Fourth Quarter 2025 Financial Results For the three months ended December 31, 2025, Phathom expects to report: Net revenues of approximately $57 million ...

Financial Performance - Q3 FY26 - Net sales increased by 2.1% year-over-year (YoY) to $348.6 million[12, 13] - Adjusted EBITDA increased by 0.7% YoY to $46.1 million[12, 13] - Adjusted EBITDA margin decreased by 20 basis points (bps) YoY to 13.2%[12, 13] - Adjusted diluted EPS decreased by 14.3% YoY to $1.02[12, 13] Segment Performance - Q3 FY26 - Architectural Metals net sales decreased by 9.9% YoY to $124.4 million[23] - Architectural Services net sales increased by 0.2% YoY to $105.2 million[23] - Architectural Glass net sales increased by 0.9% YoY to $70.9 million[23] - Performance Surfaces net sales increased by 59.6% YoY to $53.0 million[23] Cash Flow and Debt - Free cash flow for the nine months ended November 29, 2025, was $48.3 million, compared to $70.4 million for the same period in the previous year[27] - Total debt as of November 29, 2025, was $255.0 million, down from $285.0 million as of March 1, 2025[27] FY26 Outlook - The company updated its full-year FY26 net sales outlook to approximately $1.39 billion (previously $1.39 billion - $1.42 billion)[41] - The company updated its full-year FY26 adjusted diluted EPS outlook to $3.40 - $3.50 (previously $3.60 - $3.90)[41] - Tariffs are estimated to reduce full-year adjusted diluted EPS by $0.30[45]

LONGBOAT KEY, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Rumble Inc. (NASDAQ: RUM) (“Rumble” or the “Company”), the Freedom-First technology platform, today announced that it has confidentially submitted a draft registration statement on Form S-4 (the “Registration Statement”) to the U.S. Securities and Exchange Commission (“SEC”) in connection with its previously announced proposed business combination with Northern Data AG (“Northern Data”). The Registration Statement includes a preliminary joint information ...

Core Insights - B&G Foods, Inc. has appointed John Ozgopoyan as Executive Vice President of Sales, effective immediately [1][2] - The company aims to enhance its focus on core brands and improve base business net sales under Ozgopoyan's leadership [2] Company Overview - B&G Foods, Inc. is based in Parsippany, New Jersey, and specializes in manufacturing, selling, and distributing high-quality branded shelf-stable and frozen foods across the U.S., Canada, and Puerto Rico [3] - The company boasts a diverse portfolio of over 50 brands, including well-known names such as B&G, B&M, Green Giant, and Crisco [3]

Core Viewpoint - International Petroleum Corporation (IPC) has made significant progress on the Blackrod Phase 1 development project, with first steam injection occurring on December 20, 2025, and first oil production expected in Q3 2026, a quarter earlier than previously anticipated [1][2]. Project Development - The Blackrod Phase 1 project is on budget, with a forecast growth capital expenditure of USD 850 million to reach first oil [2]. - As of the end of Q3 2025, IPC has incurred capital expenditures of USD 785 million, which is approximately 92% of the total growth capital guidance [2]. - The Blackrod asset is 100% owned by IPC and contains 259 million barrels of oil equivalent (MMboe) of 2P reserves and 1,025 MMboe of contingent resources as of December 31, 2024 [2]. Production Capacity - The project has regulatory approval to produce up to 80,000 barrels of oil per day (bopd) and is targeting plateau production rates of 30,000 bopd [2]. - IPC plans to provide further updates on production and cash flows during its Capital Markets Day on February 10, 2026 [2]. Company Overview - IPC is an international oil and gas exploration and production company with a portfolio of assets in Canada, Malaysia, and France, which supports both organic and inorganic growth [3]. - IPC is part of the Lundin Group of Companies and is listed on the Toronto Stock Exchange (TSX) and Nasdaq Stockholm under the symbol "IPCO" [3].

Core Viewpoint - Peloton Minerals Corporation has successfully closed a non-brokered private placement financing, raising a total of $134,100 from the issuance of 1,490,000 units, which will be utilized for lithium exploration and working capital [1][2]. Group 1: Financing Details - The private placement was conducted at a price of CDN$0.09 per unit, with each unit comprising one common share and one common share purchase warrant exercisable at $0.12 for three years [1]. - This placement marks the third tranche under the same pricing terms, bringing the cumulative total raised to $1,170,352.53 [2]. - The company incurred fees amounting to eight percent of the funds raised and issued ten percent of the units as broker warrants, which are exercisable into a unit of the offering at the offering price for sixty months [1]. Group 2: Use of Proceeds - Proceeds from the private placement will be allocated towards lithium exploration in northern Nevada and for general working capital [2]. - The company completed its maiden drilling program on the North Elko Lithium Project in November-December 2025, with results expected by the end of January 2026 [2]. Group 3: Regulatory and Compliance Information - The private placement relied on certain prospectus exemptions, including the Existing Shareholder Exemption, allowing capital raising through securities distribution to existing shareholders [3]. - The securities issued are subject to a hold period of four months and one day from the issuance date [4]. Group 4: Company Overview - Peloton Minerals Corporation holds a 100% interest in the North Elko Lithium Project, which is prospective for lithium and other critical minerals, along with interests in gold and copper projects in Nevada and Montana [6][7]. - The company is a reporting issuer in good standing in British Columbia and Ontario, with common shares listed on the CSE and trading on the OTC QB [5].